SCHEMBL12499571

SCHEMBL12499571

O=C(Nc1cc(Cl)cc(Cl)c1)Nc1ccc(O)c(Cl)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 1/20 0.75
EPHX2 P34913 3/20 0.59
EPHX1 P07099 2/20 0.59
MEN1 O00255 6/20 0.59
KMT2A Q03164 6/20 0.59
MAPT P10636 5/20 0.59
RAB9A P51151 3/20 0.59
NPSR1 Q6W5P4 1/20 0.59
LMNA P02545 5/20 0.57
HTT P42858 3/20 0.57
NPC1 O15118 3/20 0.57
ADORA3 P0DMS8 1/20 0.57
CHRM1 P11229 1/20 0.57
SLC6A2 P23975 1/20 0.57
PDE4A P27815 1/20 0.57
ADRA1A P35348 1/20 0.57
OPRM1 P35372 1/20 0.57
PDE3A Q14432 1/20 0.57
NLRP3 Q96P20 1/20 0.57
SLC2A1 P11166 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4345497 0.88 MEN1 (0.74) P2RY1EPHX2EPHX1MEN1KMT2A
SCHEMBL4347321 0.83 P2RY1 (0.61) P2RY1EPHX2EPHX1MEN1KMT2A
SCHEMBL4358566 0.83 MEN1 (0.69) EPHX2EPHX1MEN1KMT2AMAPT
SCHEMBL4341617 0.83 MAOB (0.60) P2RY1MEN1KMT2AMAPTNPSR1
SCHEMBL4353624 0.82 P2RY1 (0.68) P2RY1EPHX2EPHX1MEN1KMT2A
SCHEMBL15786287 0.81 MEN1 (0.76) P2RY1EPHX2EPHX1MEN1KMT2A
SCHEMBL11357914 0.81 ALDH1A1 (0.59) P2RY1EPHX2EPHX1MEN1KMT2A
SCHEMBL24272322 0.80 MEN1 (0.70) P2RY1EPHX2EPHX1MEN1KMT2A
SCHEMBL14758356 0.80 MEN1 (0.75) P2RY1EPHX2EPHX1MEN1KMT2A
SCHEMBL12499941 0.80 P2RY1 (0.70) P2RY1EPHX2EPHX1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583509-B2 Compound for treating cancer and diabetes CITY OF HOPE (US) 2023-02-21 US disclosed
US-11583509-B2 Compound for treating cancer and diabetes CITY OF HOPE (US) 2023-02-21 US disclosed
US-20220023240-A1 COMPOUND FOR TREATING CANCER AND DIABETES CITY OF HOPE 2022-01-27 US disclosed
US-20220023240-A1 COMPOUND FOR TREATING CANCER AND DIABETES CITY OF HOPE 2022-01-27 US disclosed
US-10588854-B2 Polymer implants for treatment of metabolic disorders UNIVERSITY OF SOUTH CAROLINA (US) 2020-03-17 US disclosed
US-20190000749-A1 Polymer Implants for Treatment of Metabolic Disorders NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-01-03 US disclosed
US-10092508-B2 Polymer implants for treatment of metabolic disorders UNIVERSITY OF SOUTH CAROLINA (US) 2018-10-09 US disclosed
US-20170367974-A1 Polymer Implants For Treatment Of Metabolic Disorders UNIVERSITY OF SOUTH CAROLINA 2017-12-28 US disclosed
US-9808434-B2 Compound for treating cancer and diabetes CITY OF HOPE (US) 2017-11-07 US disclosed
US-9808434-B2 Compound for treating cancer and diabetes CITY OF HOPE (US) 2017-11-07 US disclosed
US-20160354327-A1 COMPOUND FOR TREATING CANCER AND DIABETES CITY OF HOPE 2016-12-08 US disclosed
US-20160354327-A1 COMPOUND FOR TREATING CANCER AND DIABETES CITY OF HOPE 2016-12-08 US disclosed
WO-2012103523-A2 NOVEL MODULATORS OF DEVELOPMENT OF ADIPOCYTE AND CANCER CELLS RAHBAR SAMUEL (US) 2012-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170367974-A1 Polymer Implants For Treatment Of Metabolic Disorders LRBA, FABP4, APMAP P2RY1 3152/4885EPHX2 4768/4885EPHX1 4477/4885
US-10588854-B2 Polymer implants for treatment of metabolic disorders LRBA, FABP4, APMAP P2RY1 3152/4885EPHX2 4768/4885EPHX1 4477/4885
US-20220023240-A1 COMPOUND FOR TREATING CANCER AND DIABETES TP53, VHL, SLC2A4 P2RY1 4063/4885EPHX2 3211/4885EPHX1 3055/4885
US-11583509-B2 Compound for treating cancer and diabetes TP53, VHL, SLC2A4 P2RY1 4063/4885EPHX2 3211/4885EPHX1 3055/4885
US-10092508-B2 Polymer implants for treatment of metabolic disorders LRBA, FABP4, APMAP P2RY1 3152/4885EPHX2 4768/4885EPHX1 4477/4885
US-20160354327-A1 COMPOUND FOR TREATING CANCER AND DIABETES TP53, VHL, SLC2A4 P2RY1 4063/4885EPHX2 3211/4885EPHX1 3055/4885
US-20190000749-A1 Polymer Implants for Treatment of Metabolic Disorders LRBA, FABP4, APMAP P2RY1 3152/4885EPHX2 4768/4885EPHX1 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.